Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct FXa inhibitor with IC50 of 0.7 nM.
Rivaroxaban (BAY 59-7939) displays >10,000-fold greater selectivity than for other serine proteases, also inhibits prothrombinase activity (IC50=2.1 nM).
Rivaroxaban (BAY 59-7939) inhibits endogenous FXa more potently in human than rat plasma (IC50 21 nM vs 290 nM).
Rivaroxaban (BAY 59-7939) reduces venous thrombosis dose dependently (ED50=0.1 mg/kg i.v.) in a rat venous stasis model.
Rivaroxaban (BAY 59-7939) is orally active.
